Newsfeeds Archive - Page 26 of 56

2 minute read

This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection

Yesterday, 2:52 PM

Numerous biopharma companies are working on enhancing first-generation or “classical” psychedelics. They're tuning down the side effects, and protecting their findings along the way.

MSSTF

2 minute read

Reunion Neuroscience Enters Compliance Period, Struggles To Remain NASDAQ Listed

By Lara Goldstein

April 25, 4:32 PM

Reunion Neuroscience (NASDAQ: REUN) no longer meets the minimum required $1.00 per-common-share for continued listing on the Nasdaq.

REUN

2 minute read

New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings

By Lara Goldstein

April 25, 4:19 PM

Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) is advancing the development of its novel compounds family of next-gen MDMA analogs. So far, Mydecine's compounds show promising pharmacokinetics (PK) and pharmacodynamics (PD) in preclinical models.

MYCOF

2 minute read

Mia Khalifa Joins Magic Mushrooms Company, Here’s What She’ll Be Doing

By Lara Goldstein

April 25, 3:58 PM

Canada-based mushrooms producer Red Light Holland Corp. (OTCQB: TRUFF) has launched a collaboration with former adult film performer and social media star Mia Khalifa.

TRUFF

2 minute read

New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market

By Lara Goldstein

April 25, 1:30 PM

Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual treatments with the substances.

IXHL

3 minute read

Psyched: LSD For Major Depression, Canada’s Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More

By Lara Goldstein

April 24, 3:57 PM

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a treatment of Major Depressive Disorder (MDD).

AWKNF

2 minute read

Psyched Clinical Trials: Australian Univ. Pursues MDMA, MEAI Compound About To Set Off

By Lara Goldstein

April 20, 2:48 PM

Monash University Engages LaNeo MDMA Australian Monash University’s psychedelics research lab has contracted MDXX-class molecules developer PharmAla Biotech to manufacture and supply its clinical-grade MDMA LaNeo for an upcoming Phase 2 clinical study.

CMND

2 minute read

Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up

By Lara Goldstein

April 20, 2:24 PM

Orphan and rare diseases drug company Lobe Sciences Ltd. (OTCQB: LOBEF) is set to acquire Altemia & Company LLC.

LOBEF

2 minute read

Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds

By Lara Goldstein

April 20, 9:12 AM

Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD.

DRUG

2 minute read

Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism

By Lara Goldstein

April 20, 9:02 AM

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started <

NMLSF